University College London
APOA4 T347S variant linked to reduced plasma TAOS in diabetic patients
Published in Medicine and Law Weekly, October 22nd, 2004
"Apolipoprotein A-IV (apoA-IV) has been postulated to be antiatherogenic. Transgenic APOA4/Apoe-/- mice are protected against atherosclerosis, with plasma apoA-IV displaying antioxidant activity in vitro. In humans, there is an inverse relationship between apoA-IV levels and risk of coronary heart disease (CHD). Furthermore, the APOA4 T347S rare allele has been associated with increased risk of CHD and reduced apoA-fV levels. Reduced total antioxidant status (TAOS) due to increased oxidative stress is implicated in the process of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Alliance for Aging Research
Hutchinson, Baucus, McClellan receive awards for support of research on aging - Alteon, Inc.
Composition-of-matter patent issued covering A.G.E. Crosslink Breakers - Arrowhead Research Corporation
Rights granted to more than 80 new patents, applications from Caltech - Bristol-Myers Squibb
U.S. Government to collect $11.3M for expenses from silicone breast implants - Business Update
Environmental groups, biolab reach settlement agreement - Cancer Screening
Preventive healthcare can overcome barriers of race, socioeconomic status - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
